Abstract

BackgroundIn the presence of heterogeneous treatment effects, it is desirable to divide patients into subgroups based on their expected response to treatment. This is formalised via a personalised treatment recommendation: an algorithm that uses biomarker measurements to select treatments. It could be that multiple, rather than single, biomarkers better predict these subgroups. However, finding the optimal combination of multiple biomarkers can be a difficult prediction problem.MethodsWe described three parametric methods for finding the optimal combination of biomarkers in a personalised treatment recommendation, using randomised trial data: a regression approach that models outcome using treatment by biomarker interactions; an approach proposed by Kraemer that forms a combined measure from individual biomarker weights, calculated on all treated and control pairs; and a novel modification of Kraemer’s approach that utilises a prognostic score to sample matched treated and control subjects. Using Monte Carlo simulations under multiple data-generating models, we compare these approaches and draw conclusions based on a measure of improvement under a personalised treatment recommendation compared to a standard treatment. The three methods are applied to data from a randomised trial of home-delivered pragmatic rehabilitation versus treatment as usual for patients with chronic fatigue syndrome (the FINE trial). Prior analysis of this data indicated some treatment effect heterogeneity from multiple, correlated biomarkers.ResultsThe regression approach outperformed Kraemer’s approach across all data-generating scenarios. The modification of Kraemer’s approach leads to improved treatment recommendations, except in the case where there was a strong unobserved prognostic biomarker. In the FINE example, the regression method indicated a weak improvement under its personalised treatment recommendation algorithm.ConclusionsThe method proposed by Kraemer does not perform better than a regression approach for combining multiple biomarkers. All methods are sensitive to misspecification of the parametric models.

Highlights

  • In the presence of heterogeneous treatment effects, it is desirable to divide patients into subgroups based on their expected response to treatment

  • In order to avoid the confounding between treatment assignment and outcome, it is considered optimal that personalised treatment recommendation (PTR)’s are estimated from randomised controlled trial (RCT) data

  • A composite moderator is derived from the individual moderator weights and used to derive a PTR

Read more

Summary

Introduction

In the presence of heterogeneous treatment effects, it is desirable to divide patients into subgroups based on their expected response to treatment This is formalised via a personalised treatment recommendation: an algorithm that uses biomarker measurements to select treatments. Given a patient population with heterogeneous treatment response, it might be possible to produce an algorithm for clinical use that provides a recommendation for treatment based on measurable traits (biomarkers). When the treatment choice is binary (the situation considered in this paper), the algorithm may recommend a treatment over an alternative for values of a single moderating biomarker, or a weighted combination of multiple moderating biomarkers. Such an algorithm is referred to as a personalised treatment recommendation (PTR). A composite moderator is derived from the individual moderator weights and used to derive a PTR

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call